Risk factors

Vivos Therapeutics (VVOS) risk factors

Item 1A of every Vivos Therapeutics, Inc. 10-K on file, and what changed from one year to the next.

Open VVOS in Gloomberb →
  • FY2025 10-K risk factors

    47 risks, 8 new, 4 dropped, 6 reworded since the prior year. Vivos expanded its business model through the SCN acquisition, financing it with an $8.25 million Streeterville note and significant equity issuance.

    Filed Apr 15, 2026
  • FY2024 10-K risk factors

    43 risks. Operating losses and negative cash flows dominate our risks, alongside reliance on The Vivos Method and stringent FDA medical device regulations.

    Filed Mar 31, 2025